ERBB2 and breast cancer: In this study, the responsiveness to PCI of MH3-B1/rGel was primarily evaluated in 2 HER2 overexpressing cell lines; the human breast cancer cell line SK-BR-3 and the human ovarian cancer cell line SKOV-3 (Fig. 1A).